Expression of genes encoding centrosomal proteins and the humoral response against these proteins in chronic myeloid leukemia

Abstract

As the extent of centrosome abnormalities in chronic myeloid leukemia (CML) correlates with disease stage and karyotype alterations, abnormal expression of genes encoding centrosomal proteins may be an early prognostic marker of disease progression. In the present study, we showed that in comparison with healthy controls, the expression of four centrosomal genes (AURKA, HMMR, PLK1 and ESPL1) in the peripheral blood of CML patients was significantly enhanced at diagnosis and decreased to the basal level in most patients treated with imatinib mesylate for three months. In the remaining patients (17%), this decrease was delayed and was associated with worse overall survival. The detection of antibodies in sera showed that patients with higher overall antibody production had superior outcomes in terms of achieving major molecular response and failure-free survival. These data suggest that the dynamics of the response of centrosomal genes should be considered as a risk factor and immunity against centrosomal proteins may contribute to treatment response.

Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML

“…Furthermore, the observed correlations between the expression levels of ESPL1/PTTG1 and PTTG1/PTTG1IP confirm the state of knowledge about the functional interaction of these proteins on a genetic level also for CML patients [28,37]. This is the first comprehensive examination of transcript levels of ESPL1, PTTG1 and PTTG1IP in CML patients, and the observed overexpression confirms the role of ESPL1 as a surrogate marker of proliferation in CML [38,39]. Our findings further support the hypothesis that increased activity of Separase in CML patients may concur with an altered expression of ESPL1 [21].…”

Polo-like kinase 1 Decrease During Induction Therapy Could Indicate Good Treatment Response, Favorable Risk Stratification, and Prolonged Survival in Pediatric Acute Lymphoblastic Leukemia: [RETRACTED]

“…PLK1 is overexpressed in various hematological malignancies, according to previous studies 17,24,25 . A study claims that PLK1 in peripheral blood and BMMCs is higher in pediatric AML patients than in healthy controls 24 .…”

“…A study claims that PLK1 in peripheral blood and BMMCs is higher in pediatric AML patients than in healthy controls 24 . PLK1 in peripheral blood leukocytes is also increased in chronic myeloid leukemia patients compared with healthy controls 25 . In pediatric ALL patients, the dysregulation of PLK1 is still controversial 17,18 .…”

“…24 PLK1 in peripheral blood leukocytes is also increased in chronic myeloid leukemia patients compared with healthy controls. 25 In pediatric ALL patients, the dysregulation of PLK1 is still controversial. 17,18 This study discovered that PLK1 in BMMCs was increased in pediatric ALL patients compared with controls; at the same time, PLK1 had a good capacity to discriminate pediatric ALL patients from controls.…”

“…PLK1 is overexpressed in various hematological malignancies, according to previous studies. 17,24,25 A study claims that PLK1 in peripheral blood and BMMCs is higher in pediatric AML patients than in healthy controls. 24 PLK1 in peripheral blood leukocytes is also increased in chronic myeloid leukemia patients compared with healthy controls.…”